Sandra Hanna

Tbo-filgrastim (Granix) is FDA approved to reduce the duration of severe neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy with significant evidence of febrile neutropenia.

Bloxiverz, manufactured by Éclat Pharmaceuticals, is the first and only FDA-approved neostigmine methylsulfate injection.